INTRODUCTION
In 2007, approximately 38% of American adults reported using complementary and alternative medicine (CAM) during the previous year. 1 Common reasons for CAM use include disease prevention, 1-3 chronic disease therapy (e.g., arthritis, cancer, depression), [1] [2] [3] [4] [5] and treatment of symptoms, [1] [2] [3] including those of diabetes mellitus. 6, 7 Among CAM modalities, dietary supplement use is most common, with 17.7% of American adults reporting using these products. 1 Sales of dietary supplements in the U.S.
have grown from $8.8 billion in 1994 3 to $14.8 billion in 2007. 8 Consumers may seek information about CAM from various sources, including health food store employees (HFSEs). [9] [10] [11] Given that HFSEs are not required to have formal training or be licensed 9, 11 their advice may be incomplete or inappropriate. 9, 10 Previous studies examining the advice provided by
HFSEs to simulated shoppers with a "documented diagnosis" (e.g., breast cancer, HIV infection) found that their recommendations vastly diverged from standards of care. Their advice ranged from expensive and potentially contraindicated products [10] [11] [12] to one HFSE who advocated discontinuing tamoxifen for breast cancer. 10 Although prior studies examined the advice provided by HFSEs for specific diagnoses, people often use CAM to treat their symptoms.
1,2,13 Thus, it is important to examine the advice provided to consumers who present to HFSEs with symptoms, particularly those associated with a serious illness. We conducted a pilot study to examine advice provided by HFSEs and community pharmacists to someone with symptoms of Type 1 diabetes. Diabetes is a prevalent condition with distinctive symptoms 14 and can pose significant health risks if untreated, especially for Type 1 diabetes. 15, 16 We included community pharmacists because they often provide health advice to consumers, 17, 18 including CAM-related information. 17, 19 To our knowledge, no study examined pharmacists' advice regarding undiagnosed Type 1 diabetes. We examined whether HFSEs and pharmacists: (1) recognized the symptoms of diabetes; and (2) recommended physician follow-up for these symptoms. In addition, we examined the monthly costs of recommended products.
METHODS
The study protocol was approved by 
Procedures
To assess the subjects' actual behaviors, we used a standardized actor posing as a customer, a strategy that has been used successfully in previous studies of HFSs 10, 12 The actor was a 22-year-old, thin, Caucasian male who described an indolent onset of diabetes symptoms (malaise, fatigue, poor concentration, polyphagia, weight loss, polydipsia, and polyuria); the literature indicates that some adults who develop Type 1 diabetes have a prolonged onset of symptoms. 20 According to the script ( Fig. 1) , he recently moved to the area for graduate school and lacked a primary care physician. For credibility, his symptoms were framed in terms of poor academic and social performance. He wore form-fitting clothing and carried a nearly-empty water bottle to each visit. He inquired about potential diagnoses for his condition, and asked for recommendations to alleviate his symptoms. If by the end of the interview, the subject had not voluntarily recommended a physician visit, the actor asked (i.e., "prompted") whether he should do so and over what time frame. The actor completed a data collection form immediately after the visit. Each visit lasted approximately 10-15 minutes. We approached quality control in two ways. First, two academic internists reviewed our script for clinical plausibility. Second, issues that arose during data collection, coding, and analysis were discussed and resolved at weekly meetings.
Measures
We had three primary outcomes: (1) Recognition of diabetes as a potential diagnosis (mentioned explicitly or as part of the differential diagnosis); (2) Recommendation for physician followup; and, (3) Recommended products and their monthly costs. All three authors independently coded the outcomes using the actor's field notes. Recommendations for physician follow-up were coded as three dichotomous variables: whether a recommendation was made; whether it was unprompted; and, urgency of follow-up (i.e., within 1 week). Recommended products were classified according to their primary ingredients. On rare occa-
• "I just moved here for grad school at UNC." For realism, the flow of conversation was allowed to vary naturally between individual visits, as appropriate; however, all seven symptoms of Type 1 diabetes were disclosed at every visit.
probes Figure 1 . Type 1 diabetes mellitus script used by our standardized actor during site visits.
sions when there were disagreements, we resolved differences through discussion during weekly meetings. We also calculated the monthly product costs based on the minimum amount of product necessary for a single 30-day course, as recommended by the subject.
RESULTS

Recognition of Diabetes
Four of the eight (50%) pharmacists mentioned diabetes as a potential diagnosis (Table 1) ; pharmacist stated that diabetes was not a possible diagnosis. Other diagnoses mentioned by pharmacists included infectious mononucleosis and a malabsorptive disorder. In contrast, two of 12 (17%) HFSEs mentioned diabetes as a potential diagnosis. The remaining ten offered various diagnoses (e.g., "adrenal exhaustion," anorexia, "mold infestation").
Physician Follow-Up
All eight pharmacists recommended a physician visit, seven (88%) of whom did so without prompting. Six pharmacists recommended an urgent (i.e., < 1 week) visit. Of 12 HFSEs, three (25%) made an unprompted recommendation for a physician visit, and three recommended a visit only after being prompted. Of the 6 HFSEs recommending a physician visit, two (33%) recommended an urgent visit. Interestingly, two HFSEs stated that a physician visit was unnecessary, and two others (both independent stores) explicitly advised against a physician visit. Their rationale was that the physician would likely overlook the underlying illness ("mold infestation" and "adrenal exhaustion"). One subject further cautioned that a physician would "just give [the actor] Ritalin" to curb fatigue.
Recommended Products
Only one pharmacist recommended a product-a multivitamin with a monthly cost of $13.99. Conversely, all six independent and three of the six (50%) chain HFSEs recommended at least one product. Independent HFSEs often recommended herbal products, whereas chain-affiliated HFSEs frequently offered proprietary multivitamins. The most common ingredients (across all products) included Rhodiola rosea, Ashwagandha, Ginseng, and Guarana. Independent HFSEs recommended more products than those in chain HFSEs (mean: two versus one, respectively, data not shown). The total monthly costs for 
DISCUSSION
This pilot study is the first to report advice provided by HFSEs and community pharmacists to a standardized actor who portrayed undiagnosed Type 1 diabetes symptoms. We wish to highlight three findings. First, under-recognition of diabetes was common in both groups, even though a young, thin person described classic symptoms of Type 1 diabetes. Although pharmacists were more likely to consider diabetes as a potential diagnosis than HFSEs (50% vs. 17%), we were surprised that half of the pharmacists did not recognize this diagnosis in someone describing hallmark symptoms. Second, six of eight (75%) pharmacists and 2 of 12 (17%) HFSEs recommended that the actor see a physician within a week. Notably, 4 HFSEs told the actor that a physician visit was unnecessary; in two of these instances, the actor was explicitly discouraged from seeing a physician. Lastly, nine HFSEs recommended products that were often expensive. Failing to see a physician and using CAM could delay the diagnosis and appropriate management of Type 1 diabetes and lead to serious consequences. 15, 20 Although our findings are novel, this study has several limitations. First, we used a single actor. Although he used a script to standardize the interactions, it is possible that pharmacists and HFSEs were influenced by characteristics of our actor. Second, we could neither audiotape discussions nor collect individual data on subjects without informed consent. This limited our ability to conduct additional analyses. Third, our study was small and limited in geographic scope, and independent pharmacies were excluded, which may limit the generalizability of our findings. Lastly, potential heterogeneity in advice received from different pharmacists and HFSEs is limited, as we interviewed only one subject per site.
CONCLUSIONS
We provide preliminary empirical evidence that advice provided by HFSEs and community pharmacists may be both inappropriate, and potentially harmful, to persons with potentially time-critical illnesses (e.g., Type 1 diabetes). Clinicians should be aware of the potential misinformation regarding symptom management being provided elsewhere. Future research should be performed to confirm our findings in a larger sample and determine whether the results generalize to other conditions. Such data could be used to develop strategies that help HFSEs and pharmacists recognize when a referral to a physician may be necessary.
